Managed Healthcare Executive12d
CS1, an HDAC Inhibitor, Appears to Reverse Remodeling in PAH
The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...
Sickle Cell Disease News15d
Bone marrow transplant in teen years may lower stroke risk in SCD
Undergoing a bone marrow transplant during adolescence, but not in adulthood, may lower the risk of stroke with SCD, a mouse study suggests.
Hosted on MSN1mon
Novel PET approach identifies early signs of pulmonary arterial hypertension
A new molecular imaging technique— 18 F-FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early ...
Managed Healthcare Executive14d
PET Imaging Could Help Track PAH Onset, Therapy Response, Study Finds
New research could pave the way toward a new method of pulmonary arterial hypertension diagnosis and monitoring.
Medscape22d
The Emergence of New Therapeutic Targets in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a vascular remodeling disease that pathologically increases pulmonary vascular resistance. Ultimately, this leads to right ventricular failure and ...